TABLE 1.
Patient baseline and primary diagnosis data
| Parameter | Safety population (N = 76) |
|---|---|
| Age, years | |
| Median | 57.5 |
| (minimum, maximum) | (34.3, 77.9) |
| Female, n (%) | 76 (100.0) |
| Race, n (%) | |
| White | 68 (89.5) |
| Black | 2 (2.6) |
| Asian | 4 (5.3) |
| Other a | 2 (2.6) |
| Hormone‐receptor status, n (%) | |
| Positive | 57 (75.0) |
| Negative | 18 (23.7) |
| Missing | 1 (1.3) |
| HER2 status, n (%) | |
| Positive | 10 (13.2) |
| Negative | 66 (86.8) |
| Triple‐negative disease, n (%) | |
| Yes | 17 (22.4) |
| No | 58 (76.3) |
| Missing | 1 (1.3) |
| Number of prior hormone therapies, n (%) | |
| 0 | 38 (50.0) |
| 1 | 14 (18.4) |
| 2 | 16 (21.1) |
| Unknown | 8 (10.5) |
| Number of prior chemotherapy treatments for advanced disease, n (%) | |
| 0 | 2 (2.6) |
| 1 | 15 (19.7) |
| 2 | 59 (77.6) |
| Any taxane, n (%) | |
| Yes | 71 (93.4) |
| No | 5 (6.6) |
| Any anthracycline, n (%) | |
| Yes | 61 (80.3) |
| No | 15 (19.7) |
| Number of sites of disease, n (%) | |
| Mean (SD) | 2.3 (1.19) |
| (minimum, maximum) | (1, 6) |
| Sites of disease, n (%) | |
| Liver | 38 (50.0) |
| Lung | 33 (43.4) |
| Lymph nodes | 33 (43.4) |
| Bone | 27 (35.5) |
| Chest wall | 10 (13.2) |
| Other | 29 (38.2) |
Abbreviations: HER2, human epidermal growth factor receptor 2; SD, standard deviation.
a
Includes mixed race or missing.
[Correction added on 12 November 2022, after first online publication: Data corresponding to “Triple‐negative disease, n (%)” in Table 1 was corrected in this version.]